For instance, PFDN1 can directly repress the transcription of cyclin A and thus promote lung cancer development (6); outlier PFDN2 expression can be detected in urine, which could serve as a biomarker for bladder cancer (7); PFDN5 could modulate c-MYC transcriptional regulatory activity (8). Here, PFDN2 is linked to urinary bladder cancer.